{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:16:00Z","timestamp":1790504160765,"version":"4.1.0"},"reference-count":96,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Background. Dialysis treatment is improving, but several long-term problems remain unsolved, including metabolic bone disease linked to chronic kidney disease (CKD-MBD). The availability of new, efficacious but expensive drugs (intravenous calcimimetic agents) poses ethical problems, especially in the setting of budget limitations. Methods. Reasons of choice, side effects, biochemical trends were discussed in a cohort of 15 patients (13% of the dialysis population) who stared treatment with intravenous calcimimetics in a single center. All patients had previously been treated with oral calcimimetic agents; dialysis efficacy was at target in 14\/15; hemodiafiltration was employed in 10\/15. Median Charlson Comorbidity Index was 8. The indications were discussed according to the principlist ethics (beneficience, non maleficience, justice and autonomy). Biochemical results were analyzed to support the clinical-ethical choices. Results. In the context of a strict clinical and biochemical surveillance, the lack of side effects ensured \u201cnon-maleficence\u201d; efficacy was at least similar to oral calcimimetic agents, but tolerance was better. Autonomy was respected through a shared decision-making model; all patients appreciated the reduction of the drug burden, and most acknowledged better control of their biochemical data. The ethical conflict resides in the balance between the clinical \u201cbeneficience, non-maleficience\u201d advantage and \u201cjustice\u201d (economic impact of treatment, potentially in attrition with other resources, since the drug is expensive and included in the dialysis bundle). The dilemma is more relevant when a patient\u2019s life expectancy is short (economic impact without clear clinical advantages), or when non-compliance is an issue (unclear advantage if the whole treatment is not correctly taken). Conclusions. In a context of person-centered medicine, autonomy, beneficence and non-maleficence should weight more than economic justice. While ethical discussions are not aimed at finding \u201cthe right answer\u201d but asking \u201cthe right questions\u201d, this example can raise awareness of the importance of including an ethical analysis in the choice of \u201ceconomically relevant\u201d drugs.<\/jats:p>","DOI":"10.3390\/ijerph17041238","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T04:06:01Z","timestamp":1582085161000},"page":"1238","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["New Intravenous Calcimimetic Agents: New Options, New Problems. An Example on How Clinical, Economical and Ethical Considerations Affect Choice of Treatment"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2632-4009","authenticated-orcid":false,"given":"Giorgina Barbara","family":"Piccoli","sequence":"first","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Torino, 10124 Torino, Italy"},{"name":"Nephrologie, Centre Hospitalier Le Mans, 72037 Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Trabace","sequence":"additional","affiliation":[{"name":"Nephrologie, Centre Hospitalier Le Mans, 72037 Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4853-180X","authenticated-orcid":false,"given":"Antoine","family":"Chatrenet","sequence":"additional","affiliation":[{"name":"Nephrologie, Centre Hospitalier Le Mans, 72037 Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Alberto","family":"Carranza de La Torre","sequence":"additional","affiliation":[{"name":"Nephrologie, Centre Hospitalier Le Mans, 72037 Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lurlinys","family":"Gendrot","sequence":"additional","affiliation":[{"name":"Nephrologie, Centre Hospitalier Le Mans, 72037 Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Nephrologie, Centre Hospitalier Le Mans, 72037 Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antioco","family":"Fois","sequence":"additional","affiliation":[{"name":"Nephrologie, Centre Hospitalier Le Mans, 72037 Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Santagati","sequence":"additional","affiliation":[{"name":"Nephrologie, Centre Hospitalier Le Mans, 72037 Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Saulnier","sequence":"additional","affiliation":[{"name":"Statistical laboratory, University of Angers, 49035 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0381-765X","authenticated-orcid":false,"given":"Nicola","family":"Panocchia","sequence":"additional","affiliation":[{"name":"Nephrology Department, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.5414\/CNP70496","article-title":"Patients undergoing dialysis therapy for 30 years or more survive with serious osteoarticular disorders","volume":"70","author":"Yamamoto","year":"2008","journal-title":"Clin. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/ndt\/gfn706","article-title":"Characteristics of dialysis-related amyloidosis in patients on haemodialysis therapy for more than 30 years","volume":"24","author":"Otsubo","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1744-9987.2007.00490.x","article-title":"Characteristics of Patients on Hemodialysis Therapy for More Than 30 Years","volume":"11","author":"Otsubo","year":"2007","journal-title":"Ther. Apher. Dial."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/ndt\/13.5.1226","article-title":"Patients surviving more than 10 years on haemodialysis. The natural history of the complications of treatment","volume":"13","author":"Harris","year":"1998","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/ndt\/17.8.1440","article-title":"Patients on renal replacement therapy for 20 or more years: A clinical profile","volume":"17","author":"Piccoli","year":"2002","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/ckj\/sfs011","article-title":"Long-term haemodialysis survival","volume":"5","author":"Heaf","year":"2012","journal-title":"Clin. Kidney J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/ndt\/gft514","article-title":"Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?","volume":"29","author":"Cozzolino","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2018.08.046","article-title":"CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies","volume":"278","author":"Reiss","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.semnephrol.2018.08.001","article-title":"Update on Chronic Kidney Disease Mineral and Bone Disorder in Cardiovascular Disease","volume":"38","author":"Lunyera","year":"2018","journal-title":"Semin. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1056\/NEJM199301213280304","article-title":"Effect of Serum Parathyroid Hormone and Bone Marrow Fibrosis on the Response to Erythropoietin in Uremia","volume":"328","author":"Rao","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/1744-9987.12685","article-title":"Emerging Association between Parathyroid Hormone and Anemia in Hemodialysis Patients","volume":"22","author":"Tanaka","year":"2018","journal-title":"Ther. Apher. Dial."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.2174\/1871530319666190215150410","article-title":"Parathyroid Hormone and Ischemic Cerebrovascular Event","volume":"19","author":"Altay","year":"2019","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cca.2018.03.028","article-title":"Circulating parathyroid hormone and risk of hypertension: A meta-analysis","volume":"482","author":"Zhang","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sofronie, A.C., Kooij, I., Bursot, C., Santagati, G., Coindre, J.-P., and Piccoli, G.B. (2018). Full normalization of severe hypertension after parathryoidectomy\u2014A case report and systematic review. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-0900-y"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s11255-011-0111-y","article-title":"Spontaneous and serial rupture of both Achilles tendons associated with secondary hyperparathyroidism in a patient receiving long-term hemodialysis","volume":"45","author":"Park","year":"2013","journal-title":"Int. Urol. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.surg.2007.11.019","article-title":"Cognitive changes after parathyroidectomy in patients with secondary hyperparathyroidism","volume":"143","author":"Chou","year":"2008","journal-title":"Surgery"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lourida, I., Thompson-Coon, J., Dickens, C.M., Soni, M., Ku\u017ama, E., Kos, K., and Llewellyn, D.J. (2015). Parathyroid Hormone, Cognitive Function and Dementia: A Systematic Review. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127574"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00234-006-0198-5","article-title":"Regional cerebral blood flow abnormalities in patients with primary hyperparathyroidism","volume":"49","author":"Cermik","year":"2007","journal-title":"Neuroradiology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.clineuro.2008.06.004","article-title":"Dementia as presenting symptom of primary hyperparathyroidism: Favourable outcome after surgery","volume":"110","author":"Papageorgiou","year":"2008","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1172\/JCI109118","article-title":"Effect of Parathyroid Hormone and Uremia on Peripheral Nerve Calcium and Motor Nerve Conduction Velocity","volume":"62","author":"Goldstein","year":"1978","journal-title":"J. Clin. Investig."},{"key":"ref_21","first-page":"S5","article-title":"Neurotoxicity of parathyroid hormone in uremia","volume":"17","author":"Massry","year":"1985","journal-title":"Kidney Int. Suppl."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/1744-9987.12683","article-title":"Secondary Hyperparathyroidism and Protein-Energy Wasting in End-Stage Renal Disease","volume":"22","author":"Komaba","year":"2018","journal-title":"Ther. Apher. Dial."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yamamoto, S., Karaboyas, A., Komaba, H., Taniguchi, M., Nomura, T., Bieber, B.A., De Sequera, P., Christensson, A., Pisoni, R.L., and Robinson, B.M. (2018). Mineral and bone disorder management in hemodialysis patients: Comparing PTH control practices in Japan with Europe and North America: The Dialysis Outcomes and Practice Patterns Study (DOPPS). BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-1056-5"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality Risk for Dialysis Patients With Different Levels of Serum Calcium, Phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1542-4758.2007.00190.x","article-title":"Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: The Japan dialysis outcomes and practice patterns study","volume":"11","author":"Kimata","year":"2007","journal-title":"Hemodial. Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1053\/ajkd.2001.29254","article-title":"Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation","volume":"38","author":"Avram","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2215\/CJN.12941213","article-title":"Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: The DOPPS study","volume":"7","author":"Tentori","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/sdi.12275","article-title":"Targeting Parathyroid Hormone Levels in Dialysis Patients","volume":"27","author":"Saab","year":"2014","journal-title":"Semin. Dial."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7326\/M17-2640","article-title":"Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease\u2013Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update","volume":"168","author":"Ketteler","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/j.ajkd.2017.07.019","article-title":"KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD)","volume":"70","author":"Isakova","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl., 7, 1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"ref_32","unstructured":"(2017). Etelcalcetide for Treating Secondary Hyperparathyroidism: Technology Appraisal Guidance [TA448], National Institute for Health and Care Excellence."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/j.ajkd.2018.11.007","article-title":"Calcimimetics and Bundled Reimbursement","volume":"73","author":"Lin","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Piccoli, G.B., Cabiddu, G., Breuer, C., Jadeau, C., Testa, A., and Brunori, G. (2019). Dialysis Reimbursement: What Impact Do Different Models Have on Clinical Choices?. J. Clin. Med., 8.","DOI":"10.3390\/jcm8020276"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2215\/CJN.09550818","article-title":"Variability in Cinacalcet Prescription across US Hemodialysis Facilities","volume":"14","author":"Fuller","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1053\/j.ajkd.2018.03.027","article-title":"Association of Medicare\u2019s Bundled Payment Reform With Changes in Use of Vitamin D Among Patients Receiving Maintenance Hemodialysis: An Interrupted Time-Series Analysis","volume":"72","author":"Spoendlin","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/1475-6773.12713","article-title":"Payment Reform and Health Disparities: Changes in Dialysis Modality under the New Medicare Dialysis Payment System","volume":"53","author":"Turenne","year":"2018","journal-title":"Health Serv. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.2215\/CJN.02600315","article-title":"Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing","volume":"10","author":"Karaboyas","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/1475-6773.12252","article-title":"Effect of Medicare dialysis payment reform on use of erythropoiesis stimulating agents","volume":"50","author":"Swaminathan","year":"2015","journal-title":"Health Serv. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.semnephrol.2018.05.009","article-title":"Personalized Management of Bone and Mineral Disorders and Precision Medicine in End-Stage Kidney Disease","volume":"38","author":"Jovanovich","year":"2018","journal-title":"Semin. Nephrol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2215\/CJN.09310916","article-title":"The CKD Classification System in the Precision Medicine Era","volume":"12","author":"Hall","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_42","unstructured":"Soci\u00e9t\u00e9 Francophone de N\u00e9phrologie Dialyse et Transplantation (SFNDT) (2016). Report on Chronic Dialysis in France in 2016, Soci\u00e9t\u00e9 Francophone de N\u00e9phrologie Dialyse et Transplantation."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Piccoli, G.B., Cabiddu, G., Moio, M.R., Fois, A., Cao, R., Molfino, I., Kaniassi, A., Lippi, F., Froger, L., and Pani, A. (2018). Efficiency and nutritional parameters in an elderly high risk population on hemodialysis and hemodiafiltration in Italy and France: Different treatments with similar names?. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-0948-8"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Piccoli, G.B., Nielsen, L., Gendrot, L., Fois, A., Cataldo, E., and Cabiddu, G. (2018). Prescribing Hemodialysis or Hemodiafiltration: When One Size Does Not Fit All the Proposal of a Personalized Approach Based on Comorbidity and Nutritional Status. J. Clin. Med., 7.","DOI":"10.3390\/jcm7100331"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40620-018-0497-z","article-title":"Nutritional treatment of advanced CKD: Twenty consensus statements","volume":"31","author":"Cupisti","year":"2018","journal-title":"J. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/bmj.309.6948.184","article-title":"Medical ethics: Four principles plus attention to scope","volume":"309","author":"Gillon","year":"1994","journal-title":"BMJ"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/mh.29.2.65","article-title":"Principlism or narrative ethics: Must we choose between them?","volume":"29","author":"McCarthy","year":"2003","journal-title":"Med. Humanit."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2215\/CJN.04780515","article-title":"The Evolving Ethics of Dialysis in the United States: A Principlist Bioethics Approach","volume":"11","author":"Butler","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/15265161.2011.581736","article-title":"Rationing: A \u201cdecent minimum\u201d or a \u201cconsumer driven\u201d health care system?","volume":"11","author":"Paris","year":"2011","journal-title":"Am. J. Bioeth."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"(1995). Who owns medical technology?. Lancet, 345, 1125\u20131126.","DOI":"10.1016\/S0140-6736(95)90969-9"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of Etelcalcetide vs. Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of Etelcalcetide vs. Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1001\/jama.2017.4746","article-title":"Dosing of Etelcalcetide vs Cinacalcet for Secondary Hyperparathyroidism-Reply","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1001\/jama.2017.4743","article-title":"Dosing of Etelcalcetide and Cinacalcet for Secondary Hyperparathyroidism","volume":"317","author":"Hai","year":"2017","journal-title":"JAMA"},{"key":"ref_55","first-page":"1723","article-title":"A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163\/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients","volume":"32","author":"Fukagawa","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000496562","article-title":"Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients","volume":"48","author":"Xipell","year":"2019","journal-title":"Blood Purif."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.clinthera.2018.10.016","article-title":"Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study","volume":"40","author":"Shigematsu","year":"2018","journal-title":"Clin. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejphar.2018.10.021","article-title":"Pharmacology of Parsabiv\u00ae (etelcalcetide, ONO-5163\/AMG 416), a novel allosteric modulator of the calcium-sensing receptor, for secondary hyperparathyroidism in hemodialysis patients","volume":"842","author":"Harada","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1177\/0300060518786913","article-title":"Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: A short-term clinical study","volume":"46","author":"Mima","year":"2018","journal-title":"J. Int. Med. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/1744-9987.12701","article-title":"Dramatic Regression of Parathyroid Gland Swelling After Conversion of Calcimimetic Medication From Cinacalcet to Etelcalcetide","volume":"22","author":"Yoshimura","year":"2018","journal-title":"Ther. Apher. Dial."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ekir.2017.01.016","article-title":"A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism","volume":"2","author":"Yokoyama","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s10157-017-1442-5","article-title":"ONO-5163 Study Group. Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism","volume":"22","author":"Shigematsu","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1254\/fpj.150.98","article-title":"The pharmacological profile and the clinical efficacy of the world\u2019s 1st intravenous calcimimetics; etelcalcetide hydrochloride (Parsabiv\u00ae)","volume":"150","author":"Harada","year":"2017","journal-title":"Folia Pharmacol. Jpn."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5414\/CN108974","article-title":"A 12-week dose-escalating study of etelcalcetide (ONO-5163\/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients","volume":"88","author":"Yokoyama","year":"2017","journal-title":"Clin. Nephrol."},{"key":"ref_65","first-page":"396","article-title":"Etelcalcetide (Parsabiv) for Secondary Hyperparathyroidism in Adults with Chronic Kidney Disease on Hemodialysis","volume":"43","author":"Patel","year":"2018","journal-title":"Pharm. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/sdi.12734","article-title":"Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?","volume":"31","author":"Eidman","year":"2018","journal-title":"Semin. Dial."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2147\/DDDT.S134103","article-title":"Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: A review on current data and place in therapy","volume":"12","author":"Friedl","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2147\/DDDT.S160223","article-title":"Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis","volume":"12","author":"Ye","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmch.2017.12.001","article-title":"Discovery and Development of Calcimimetic and Calcilytic Compounds","volume":"57","author":"Nemeth","year":"2018","journal-title":"Prog. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.nefroe.2018.02.016","article-title":"A light in the control of secondary hyperparathyroidism. Etelcalcetide IV in haemodialysis","volume":"38","author":"Ochoa","year":"2018","journal-title":"Nefrolog\u00eda (Engl. Ed.)"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/jcph.1090","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis","volume":"58","author":"Wu","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/IJNRD.S128252","article-title":"Managing hyperparathyroidism in hemodialysis: Role of etelcalcetide","volume":"11","author":"Eidman","year":"2018","journal-title":"Int. J. Nephrol. Renov. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/ckj\/sfx125","article-title":"Old and new calcimimetics for treatment of secondary hyperparathyroidism: Impact on biochemical and relevant clinical outcomes","volume":"11","author":"Pereira","year":"2018","journal-title":"Clin. Kidney J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/0018578717733478","article-title":"Formulary Drug Review: Etelcalcetide","volume":"52","author":"Baker","year":"2017","journal-title":"Hosp. Pharm."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1358\/dot.2017.53.9.2711938","article-title":"Etelcalcetide: Injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients","volume":"53","author":"Bover","year":"2017","journal-title":"Drugs Today (Barc.)"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00223-017-0319-7","article-title":"Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism","volume":"101","author":"Yu","year":"2017","journal-title":"Calcif. Tissue Int."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bone.2017.08.026","article-title":"Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism","volume":"105","author":"Li","year":"2017","journal-title":"Bone"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2147\/TCRM.S108490","article-title":"Treatment of secondary hyperparathyroidism: The clinical utility of etelcalcetide","volume":"13","author":"Cozzolino","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40262-017-0550-4","article-title":"Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis","volume":"57","author":"Chen","year":"2018","journal-title":"Clin. Pharm."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14656566.2017.1303482","article-title":"Etelcalcetide for the treatment of secondary hyperparathyroidism","volume":"18","author":"Hamano","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s40265-016-0671-3","article-title":"Etelcalcetide: First Global Approval","volume":"76","author":"Blair","year":"2016","journal-title":"Drugs"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/psp4.12106","article-title":"Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis","volume":"5","author":"Chen","year":"2016","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40262-016-0433-0","article-title":"Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis","volume":"56","author":"Subramanian","year":"2017","journal-title":"Clin. Pharm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ekir.2016.04.002","article-title":"Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing","volume":"1","author":"Edson","year":"2016","journal-title":"Kidney Int. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Bellasi, A., Cozzolino, M., Malberti, F., Cancarini, G., Esposito, C., Guastoni, C.M., Ondei, P., Pontoriero, G., Teatini, U., and Vezzoli, G. (2019). New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology. J. Nephrol.","DOI":"10.1007\/s40620-019-00677-0"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s40273-018-0661-2","article-title":"Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal","volume":"36","author":"Rose","year":"2018","journal-title":"PharmacoEconomics"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40273-017-0605-2","article-title":"A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet","volume":"36","author":"Stollenwerk","year":"2018","journal-title":"PharmacoEconomics"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13696998.2017.1360309","article-title":"Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy","volume":"20","author":"Stollenwerk","year":"2017","journal-title":"J. Med. Econ."},{"key":"ref_89","first-page":"33","article-title":"Parsabiv Could Be Pricey Addition in Care for CKD, ESRD Patients","volume":"26","author":"Morrow","year":"2017","journal-title":"Manag. Care"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.2215\/CJN.00650114","article-title":"Dialysis Advisory Group of the American Society of Nephrology. A palliative approach to dialysis care: A patient-centered transition to the end of life","volume":"9","author":"Grubbs","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1001\/jama.1993.03510200075035","article-title":"Rationing failure. The ethical lessons of the retransplantation of scarce vital organs","volume":"270","author":"Ubel","year":"1993","journal-title":"JAMA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1399-3046.2011.01633.x","article-title":"Should we retransplant a patient who is non-adherent? A literature review and critical reflection","volume":"16","author":"Dobbels","year":"2012","journal-title":"Pediatr. Transplant."},{"key":"ref_93","first-page":"1337","article-title":"Selective retransplant after graft loss to nonadherence: Success with a second chance","volume":"9","author":"Dunn","year":"2009","journal-title":"Arab. Archaeol. Epigr."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Huesch, M.D. (2012). One and done? Equality of opportunity and repeated access to scarce, indivisible medical resources. BMC Med. Ethic., 13.","DOI":"10.1186\/1472-6939-13-11"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/15265161.2010.528509","article-title":"Stuck in the Middle: The Many Moral Challenges with Bariatric Surgery","volume":"10","author":"Hofmann","year":"2010","journal-title":"Am. J. Bioeth."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11017-016-9374-8","article-title":"The right to preventive health care","volume":"37","author":"Conly","year":"2016","journal-title":"Theor. Med. Bioeth."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/17\/4\/1238\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:57:53Z","timestamp":1760173073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/17\/4\/1238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":96,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["ijerph17041238"],"URL":"https:\/\/doi.org\/10.3390\/ijerph17041238","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]}}}